Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

among other eye conditions (marketed as Eylea), and again in August 2012 to treat metastatic colorectal cancer (marketed as Zaltrap). Both were formed in partnership with Sanofi (SNY), which was ...

Valued at $73.8 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. Companies worth $ ...

Valued at a market cap of $76.6 billion, the company’s portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst, and Zaltrap. The biotech ...

The company’s products include EYLEA injection to treat wet age-related ... inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic ...

CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and ...

Here's the rundown. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

Regeneron prioritizes returning capital to shareholders. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co ...